All In Biotech

NDA 217171 · Apellis Pharms

Syfovre

Pegcetacoplan · Intravitreal · Complement Inhibitor

Priority review

Last checked: Nov 20, 2026Latest source record: Mar 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Feb 17, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30

12 Phase 3, 6 recruiting

FAERS reports

1,546

1,088 serious, 99 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 16, 2025.

SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). ( 1 )

Mechanism: Pegcetacoplan binds to complement protein C3 and its activation fragment C3b with high affinity thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 17, 2023 Original approval · Type 3 - New Dosage Form · priority review LetterLabelReview
1 products under this application
  • SYFOVRE · PEGCETACOPLAN 15MG/0.1ML (15MG/0.1ML) · SOLUTION, INTRAVITREAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pegcetacoplan" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • visual impairment144
  • fatigue133
  • off label use131
  • vitreous floaters115
  • haemoglobin decreased94
  • haemolysis83
  • uveitis79
  • vitritis75
  • eye inflammation72
  • headache67
  • neovascular age-related macular degeneration66
  • vision blurred66

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20214
202232
2023262
2024713
2025313
2026222

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Syfovre (PEGcetacoplan/PF)

2024 spending

$5.5M

Beneficiaries

463

1,835 claims

Per beneficiary

$11,896

$22,307.17 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$1,557,241
2024$5,507,640

Part B: Syfovre (Pegcetacoplan/PF) · HCPCS J2781

2024 spending

$404M

Beneficiaries

29,338

148,576 claims

Per beneficiary

$13,766

2024 ASP limit $149.45 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$76,651,580
2024$403,855,395

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Apellis Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.